ALK-Abelló (ALKBC) Stock Overview
An allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ALKBC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
ALK-Abelló A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 257.80 |
| 52 Week High | DKK 259.90 |
| 52 Week Low | DKK 173.30 |
| Beta | 0.68 |
| 1 Month Change | 12.14% |
| 3 Month Change | 19.68% |
| 1 Year Change | 48.80% |
| 3 Year Change | 211.92% |
| 5 Year Change | 91.10% |
| Change since IPO | 935.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALKBC | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | 0.9% | 0.9% |
| 1Y | 48.8% | 26.0% | 19.8% |
Return vs Industry: ALKBC exceeded the UK Pharmaceuticals industry which returned 24.6% over the past year.
Return vs Market: ALKBC exceeded the UK Market which returned 19% over the past year.
Price Volatility
| ALKBC volatility | |
|---|---|
| ALKBC Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in GB Market | 12.0% |
| 10% least volatile stocks in GB Market | 3.1% |
Stable Share Price: ALKBC's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine ALKBC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 2,759 | Peter Halling | www.alk.net |
ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies, including grass and tree pollen, house dust mites, ragweed, Japanese cedar, peanuts, and tree nuts; adrenaline nasal sprays for emergency treatment of anaphylaxis and acute flares in chronic spontaneous urticaria; and ALK 014, a biologic for food allergies. It also provides GRAZAX/GRASTEK, a tablet for grass pollen allergy; ACARIZAX, ODACTRA, and MITICURE/SENSIMUNE, which are tablets for house dust mite allergies; ITULAZAX/ITULATEK, a tablet for tree pollen allergy; RAGWITEK/RAGWIZAX, a tablet for ragweed pollen allergy; and CEDARCURE, a tablet for Japanese cedar pollen allergy.
ALK-Abelló A/S Fundamentals Summary
| ALKBC fundamental statistics | |
|---|---|
| Market cap | DKK 58.94b |
| Earnings (TTM) | DKK 1.28b |
| Revenue (TTM) | DKK 6.56b |
Is ALKBC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALKBC income statement (TTM) | |
|---|---|
| Revenue | DKK 6.56b |
| Cost of Revenue | DKK 2.11b |
| Gross Profit | DKK 4.46b |
| Other Expenses | DKK 3.18b |
| Earnings | DKK 1.28b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 20, 2026
| Earnings per share (EPS) | 5.78 |
| Gross Margin | 67.92% |
| Net Profit Margin | 19.51% |
| Debt/Equity Ratio | 2.5% |
How did ALKBC perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/27 11:29 |
| End of Day Share Price | 2026/05/07 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ALK-Abelló A/S is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Mads Brinkmann Andersen | Berenberg |
| Jesper Ilsoe | Carnegie Investment Bank AB |